| 4.95 -0.13 (-2.56%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.11 |
1-year : | 6.86 |
| Resists | First : | 5.23 |
Second : | 5.87 |
| Pivot price | 5.27 |
|||
| Supports | First : | 4.19 |
Second : | 3.49 |
| MAs | MA(5) : | 5.09 |
MA(20) : | 5.29 |
| MA(100) : | 5.06 |
MA(250) : | 4.63 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 11 |
D(3) : | 17.7 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 7.19 | Low : | 1.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALDX ] has closed above bottom band by 5.5%. Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.09 - 5.11 | 5.11 - 5.14 |
| Low: | 4.84 - 4.87 | 4.87 - 4.9 |
| Close: | 4.89 - 4.94 | 4.94 - 4.99 |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Thu, 19 Feb 2026
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research
Thu, 19 Feb 2026
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Yahoo Finance
Wed, 18 Feb 2026
Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan
Tue, 03 Feb 2026
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance
Tue, 30 Dec 2025
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Tue, 16 Dec 2025
Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 5,100 (K) |
| Shares Short P.Month | 6,200 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29 % |
| Return on Equity (ttm) | -64.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | -6.79 |
| PEG Ratio | 0 |
| Price to Book value | 6.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|